Literature DB >> 32860527

Curdlan, zymosan and a yeast-derived β-glucan reshape tumor-associated macrophages into producers of inflammatory chemo-attractants.

Reno Debets1, Coen Govers2, Priscilla de Graaff3,4, Cor Berrevoets1, Christiane Rӧsch5, Henk A Schols5, Kees Verhoef6, Harry J Wichers7.   

Abstract

Anti-cancer T-cell responses are often halted due to the immune-suppressive micro-environment, in part related to tumor-associated macrophages. In the current study, we assessed indigestible β-glucans (oatβG, curdlan, grifolan, schizophyllan, lentinan, yeast whole glucan particles (yWGP), zymosan and two additional yeast-derived β-glucans a and b) for their physicochemical properties as well as their effects on the plasticity of human monocyte-derived macrophages that were polarized with IL-4 to immune-suppressive macrophages. Beta-glucans were LPS/LTA free, and tested for solubility, molecular masses, protein and monosaccharide contents. Curdlan, yeast-b and zymosan re-polarized M(IL-4) macrophages towards an M1-like phenotype, in particular showing enhanced gene expression of CCR7, ICAM1 and CD80, and secretion of TNF-α and IL-6. Notably, differential gene expression, pathway analysis as well as protein expressions demonstrated that M(IL-4) macrophages treated with curdlan, yeast-b or zymosan demonstrated enhanced production of chemo-attractants, such as CCL3, CCL4, and CXCL8, which contribute to recruitment of monocytes and neutrophils. The secretion of chemo-attractants was confirmed when using patient-derived melanoma-infiltrating immune cells. Taken together, the bacterial-derived curdlan as well as the yeast-derived β-glucans yeast-b and zymosan have the unique ability to preferentially skew macrophages towards a chemo-attractant-producing phenotype that may aid in anti-cancer immune responses.

Entities:  

Keywords:  Beta-glucans; Chemo-attractants; Chemokines; Macrophages

Year:  2020        PMID: 32860527     DOI: 10.1007/s00262-020-02707-4

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  44 in total

Review 1.  Role of tumor-associated macrophages in tumor progression and invasion.

Authors:  Alberto Mantovani; Tiziana Schioppa; Chiara Porta; Paola Allavena; Antonio Sica
Journal:  Cancer Metastasis Rev       Date:  2006-09       Impact factor: 9.264

Review 2.  Non-viral nano-immunotherapeutics targeting tumor microenvironmental immune cells.

Authors:  Seok-Beom Yong; Jee Young Chung; Yoonsung Song; Jaehyun Kim; Sehee Ra; Yong-Hee Kim
Journal:  Biomaterials       Date:  2019-07-31       Impact factor: 12.479

3.  Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature.

Authors:  Qiong-wen Zhang; Lei Liu; Chang-yang Gong; Hua-shan Shi; Yun-hui Zeng; Xiao-ze Wang; Yu-wei Zhao; Yu-quan Wei
Journal:  PLoS One       Date:  2012-12-28       Impact factor: 3.240

Review 4.  Much More than M1 and M2 Macrophages, There are also CD169(+) and TCR(+) Macrophages.

Authors:  Leslie Chávez-Galán; Maria L Olleros; Dominique Vesin; Irene Garcia
Journal:  Front Immunol       Date:  2015-05-26       Impact factor: 7.561

Review 5.  Targeting Tumor-Associated Macrophages as a Potential Strategy to Enhance the Response to Immune Checkpoint Inhibitors.

Authors:  Luca Cassetta; Takanori Kitamura
Journal:  Front Cell Dev Biol       Date:  2018-04-04

Review 6.  Tumor-associated macrophages: from basic research to clinical application.

Authors:  Li Yang; Yi Zhang
Journal:  J Hematol Oncol       Date:  2017-02-28       Impact factor: 17.388

Review 7.  Targeting Macrophages in Cancer: From Bench to Bedside.

Authors:  Ashleigh R Poh; Matthias Ernst
Journal:  Front Oncol       Date:  2018-03-12       Impact factor: 6.244

Review 8.  Targeting macrophages: therapeutic approaches in cancer.

Authors:  Luca Cassetta; Jeffrey W Pollard
Journal:  Nat Rev Drug Discov       Date:  2018-10-26       Impact factor: 84.694

Review 9.  TAMeless traitors: macrophages in cancer progression and metastasis.

Authors:  Shweta Aras; M Raza Zaidi
Journal:  Br J Cancer       Date:  2017-10-24       Impact factor: 7.640

10.  Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment.

Authors:  Elisa Peranzoni; Jean Lemoine; Lene Vimeux; Vincent Feuillet; Sarah Barrin; Chahrazade Kantari-Mimoun; Nadège Bercovici; Marion Guérin; Jérôme Biton; Hanane Ouakrim; Fabienne Régnier; Audrey Lupo; Marco Alifano; Diane Damotte; Emmanuel Donnadieu
Journal:  Proc Natl Acad Sci U S A       Date:  2018-04-09       Impact factor: 11.205

View more
  12 in total

Review 1.  Breaking the niche: multidimensional nanotherapeutics for tumor microenvironment modulation.

Authors:  K Laxmi Swetha; Kavya Sree Maravajjala; Shyh-Dar Li; Manu Smriti Singh; Aniruddha Roy
Journal:  Drug Deliv Transl Res       Date:  2022-06-13       Impact factor: 4.617

2.  Hepatitis E virus infection activates NOD-like receptor family pyrin domain-containing 3 inflammasome antagonizing interferon response but therapeutically targetable.

Authors:  Yang Li; Peifa Yu; Amy L Kessler; Jingyi Shu; Xiaoyan Liu; Zhaochao Liang; Jiaye Liu; Yunlong Li; Pengfei Li; Ling Wang; Yining Wang; Zhongren Ma; Aixia Liu; Ling Wang; Marco J Bruno; Robert A de Man; Maikel P Peppelenbosch; Sonja I Buschow; Lin Wang; Yijin Wang; Qiuwei Pan
Journal:  Hepatology       Date:  2021-12-05       Impact factor: 17.298

3.  Zymosan-A promotes the regeneration of intestinal stem cells by upregulating ASCL2.

Authors:  Jicong Du; Lan Fang; Jianpeng Zhao; Yike Yu; Zhenlan Feng; Yuedong Wang; Ying Cheng; Bailong Li; Fu Gao; Cong Liu
Journal:  Cell Death Dis       Date:  2022-10-20       Impact factor: 9.685

Review 4.  Manipulation of the tumor immuno-microenvironment via TAM-targeted expression of transcription factors.

Authors:  Maggie Musick; Xianzhong Yu
Journal:  Immunol Res       Date:  2022-04-29       Impact factor: 4.505

5.  Mitofusin 2 Deficiency Causes Pro-Inflammatory Effects in Human Primary Macrophages.

Authors:  Vera Khodzhaeva; Yannick Schreiber; Gerd Geisslinger; Ralf P Brandes; Bernhard Brüne; Dmitry Namgaladze
Journal:  Front Immunol       Date:  2021-08-12       Impact factor: 7.561

6.  Glutathione Metabolism Is a Regulator of the Acute Inflammatory Response of Monocytes to (1→3)-β-D-Glucan.

Authors:  Rayoun Ramendra; Mathieu Mancini; Jose-Mauricio Ayala; Lin Tze Tung; Stephane Isnard; John Lin; Jean-Pierre Routy; Anastasia Nijnik; David Langlais
Journal:  Front Immunol       Date:  2021-11-11       Impact factor: 7.561

7.  Colon Expression of Chemokines and Their Receptors Depending on the Stage of Colitis and Oat Beta-Glucan Dietary Intervention-Crohn's Disease Model Study.

Authors:  Łukasz Kopiasz; Katarzyna Dziendzikowska; Joanna Gromadzka-Ostrowska
Journal:  Int J Mol Sci       Date:  2022-01-26       Impact factor: 5.923

Review 8.  Ingestion, Immunity, and Infection: Nutrition and Viral Respiratory Tract Infections.

Authors:  Coen Govers; Philip C Calder; Huub F J Savelkoul; Ruud Albers; R J Joost van Neerven
Journal:  Front Immunol       Date:  2022-02-28       Impact factor: 7.561

9.  Continuous Exposure to Non-Soluble β-Glucans Induces Trained Immunity in M-CSF-Differentiated Macrophages.

Authors:  Bart G J Moerings; Priscilla de Graaff; Matthew Furber; Renger F Witkamp; Reno Debets; Jurriaan J Mes; Jeroen van Bergenhenegouwen; Coen Govers
Journal:  Front Immunol       Date:  2021-06-02       Impact factor: 7.561

Review 10.  Effects of Medicinal Fungi-Derived β-Glucan on Tumor Progression.

Authors:  Vaclav Vetvicka; Tamara V Teplyakova; Alexandra B Shintyapina; Tatiana A Korolenko
Journal:  J Fungi (Basel)       Date:  2021-03-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.